Inhibition of HDAC3- and HDAC6-promoted survivin expression plays an important role in SAHA-induced autophagy and viability reduction in breast cancer cells

Jane Ying Chieh Lee, Ching Wen Kuo, Shing Ling Tsai, Siao Muk Cheng, Shang Hung Chen, Hsiu Han Chan, Chun Hui Lin, Kun Yuan Lin, Chien Feng Li, Jagat R. Kanwar, Euphemia Y. Leung, Carlos Chun Ho Cheung, Wei Jan Huang, Yi Ching Wang, Chun Hei Antonio Cheung

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

SAHA is a class I HDAC/HDAC6 co-inhibitor and an autophagy inducer currently undergoing clinical investigations in breast cancer patients. However, the molecular mechanism of action of SAHA in breast cancer cells remains unclear. In this study, we found that SAHA is equally effective in targeting cells of different breast cancer subtypes and tamoxifen sensitivity. Importantly, we found that down-regulation of survivin plays an important role in SAHA-induced autophagy and cell viability reduction in human breast cancer cells. SAHA decreased survivin and XIAP gene transcription, induced survivin protein acetylation and early nuclear translocation in MCF7 and MDA-MB-231 breast cancer cells. It also reduced survivin and XIAP protein stability in part through modulating the expression and activation of the 26S proteasome and heat-shock protein 90. Interestingly, targeting HDAC3 and HDAC6, but not other HDAC isoforms, by siRNA/pharmacological inhibitors mimicked the effects of SAHA in modulating the acetylation, expression, and nuclear translocation of survivin and induced autophagy in MCF7 and MDA-MB-231 cancer cells. Targeting HDAC3 also mimicked the effect of SAHA in up-regulating the expression and activity of proteasome, which might lead to the reduced protein stability of survivin in breast cancer cells. In conclusion, this study provides new insights into SAHA's molecular mechanism of actions in breast cancer cells. Our findings emphasize the complexity of the regulatory roles in different HDAC isoforms and potentially assist in predicting the mechanism of novel HDAC inhibitors in targeted or combinational therapies in the future.

Original languageEnglish
Article number81
JournalFrontiers in Pharmacology
Volume7
Issue numberMAR
DOIs
Publication statusPublished - Mar 31 2016

Fingerprint

Autophagy
Breast Neoplasms
Protein Stability
Acetylation
Protein Isoforms
X-Linked Inhibitor of Apoptosis Protein
HSP90 Heat-Shock Proteins
Histone Deacetylase Inhibitors
Proteasome Endopeptidase Complex
Tamoxifen
Small Interfering RNA
Cell Survival
Down-Regulation
Pharmacology
Genes
Neoplasms
Proteins

Keywords

  • Breast cancer
  • HDAC
  • SAHA
  • Survivin
  • XIAP

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Inhibition of HDAC3- and HDAC6-promoted survivin expression plays an important role in SAHA-induced autophagy and viability reduction in breast cancer cells. / Lee, Jane Ying Chieh; Kuo, Ching Wen; Tsai, Shing Ling; Cheng, Siao Muk; Chen, Shang Hung; Chan, Hsiu Han; Lin, Chun Hui; Lin, Kun Yuan; Li, Chien Feng; Kanwar, Jagat R.; Leung, Euphemia Y.; Cheung, Carlos Chun Ho; Huang, Wei Jan; Wang, Yi Ching; Cheung, Chun Hei Antonio.

In: Frontiers in Pharmacology, Vol. 7, No. MAR, 81, 31.03.2016.

Research output: Contribution to journalArticle

Lee, JYC, Kuo, CW, Tsai, SL, Cheng, SM, Chen, SH, Chan, HH, Lin, CH, Lin, KY, Li, CF, Kanwar, JR, Leung, EY, Cheung, CCH, Huang, WJ, Wang, YC & Cheung, CHA 2016, 'Inhibition of HDAC3- and HDAC6-promoted survivin expression plays an important role in SAHA-induced autophagy and viability reduction in breast cancer cells', Frontiers in Pharmacology, vol. 7, no. MAR, 81. https://doi.org/10.3389/fphar.2016.00081
Lee, Jane Ying Chieh ; Kuo, Ching Wen ; Tsai, Shing Ling ; Cheng, Siao Muk ; Chen, Shang Hung ; Chan, Hsiu Han ; Lin, Chun Hui ; Lin, Kun Yuan ; Li, Chien Feng ; Kanwar, Jagat R. ; Leung, Euphemia Y. ; Cheung, Carlos Chun Ho ; Huang, Wei Jan ; Wang, Yi Ching ; Cheung, Chun Hei Antonio. / Inhibition of HDAC3- and HDAC6-promoted survivin expression plays an important role in SAHA-induced autophagy and viability reduction in breast cancer cells. In: Frontiers in Pharmacology. 2016 ; Vol. 7, No. MAR.
@article{2530a40a146243b3930fe46ddf5fbfef,
title = "Inhibition of HDAC3- and HDAC6-promoted survivin expression plays an important role in SAHA-induced autophagy and viability reduction in breast cancer cells",
abstract = "SAHA is a class I HDAC/HDAC6 co-inhibitor and an autophagy inducer currently undergoing clinical investigations in breast cancer patients. However, the molecular mechanism of action of SAHA in breast cancer cells remains unclear. In this study, we found that SAHA is equally effective in targeting cells of different breast cancer subtypes and tamoxifen sensitivity. Importantly, we found that down-regulation of survivin plays an important role in SAHA-induced autophagy and cell viability reduction in human breast cancer cells. SAHA decreased survivin and XIAP gene transcription, induced survivin protein acetylation and early nuclear translocation in MCF7 and MDA-MB-231 breast cancer cells. It also reduced survivin and XIAP protein stability in part through modulating the expression and activation of the 26S proteasome and heat-shock protein 90. Interestingly, targeting HDAC3 and HDAC6, but not other HDAC isoforms, by siRNA/pharmacological inhibitors mimicked the effects of SAHA in modulating the acetylation, expression, and nuclear translocation of survivin and induced autophagy in MCF7 and MDA-MB-231 cancer cells. Targeting HDAC3 also mimicked the effect of SAHA in up-regulating the expression and activity of proteasome, which might lead to the reduced protein stability of survivin in breast cancer cells. In conclusion, this study provides new insights into SAHA's molecular mechanism of actions in breast cancer cells. Our findings emphasize the complexity of the regulatory roles in different HDAC isoforms and potentially assist in predicting the mechanism of novel HDAC inhibitors in targeted or combinational therapies in the future.",
keywords = "Breast cancer, HDAC, SAHA, Survivin, XIAP",
author = "Lee, {Jane Ying Chieh} and Kuo, {Ching Wen} and Tsai, {Shing Ling} and Cheng, {Siao Muk} and Chen, {Shang Hung} and Chan, {Hsiu Han} and Lin, {Chun Hui} and Lin, {Kun Yuan} and Li, {Chien Feng} and Kanwar, {Jagat R.} and Leung, {Euphemia Y.} and Cheung, {Carlos Chun Ho} and Huang, {Wei Jan} and Wang, {Yi Ching} and Cheung, {Chun Hei Antonio}",
year = "2016",
month = "3",
day = "31",
doi = "10.3389/fphar.2016.00081",
language = "English",
volume = "7",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S. A.",
number = "MAR",

}

TY - JOUR

T1 - Inhibition of HDAC3- and HDAC6-promoted survivin expression plays an important role in SAHA-induced autophagy and viability reduction in breast cancer cells

AU - Lee, Jane Ying Chieh

AU - Kuo, Ching Wen

AU - Tsai, Shing Ling

AU - Cheng, Siao Muk

AU - Chen, Shang Hung

AU - Chan, Hsiu Han

AU - Lin, Chun Hui

AU - Lin, Kun Yuan

AU - Li, Chien Feng

AU - Kanwar, Jagat R.

AU - Leung, Euphemia Y.

AU - Cheung, Carlos Chun Ho

AU - Huang, Wei Jan

AU - Wang, Yi Ching

AU - Cheung, Chun Hei Antonio

PY - 2016/3/31

Y1 - 2016/3/31

N2 - SAHA is a class I HDAC/HDAC6 co-inhibitor and an autophagy inducer currently undergoing clinical investigations in breast cancer patients. However, the molecular mechanism of action of SAHA in breast cancer cells remains unclear. In this study, we found that SAHA is equally effective in targeting cells of different breast cancer subtypes and tamoxifen sensitivity. Importantly, we found that down-regulation of survivin plays an important role in SAHA-induced autophagy and cell viability reduction in human breast cancer cells. SAHA decreased survivin and XIAP gene transcription, induced survivin protein acetylation and early nuclear translocation in MCF7 and MDA-MB-231 breast cancer cells. It also reduced survivin and XIAP protein stability in part through modulating the expression and activation of the 26S proteasome and heat-shock protein 90. Interestingly, targeting HDAC3 and HDAC6, but not other HDAC isoforms, by siRNA/pharmacological inhibitors mimicked the effects of SAHA in modulating the acetylation, expression, and nuclear translocation of survivin and induced autophagy in MCF7 and MDA-MB-231 cancer cells. Targeting HDAC3 also mimicked the effect of SAHA in up-regulating the expression and activity of proteasome, which might lead to the reduced protein stability of survivin in breast cancer cells. In conclusion, this study provides new insights into SAHA's molecular mechanism of actions in breast cancer cells. Our findings emphasize the complexity of the regulatory roles in different HDAC isoforms and potentially assist in predicting the mechanism of novel HDAC inhibitors in targeted or combinational therapies in the future.

AB - SAHA is a class I HDAC/HDAC6 co-inhibitor and an autophagy inducer currently undergoing clinical investigations in breast cancer patients. However, the molecular mechanism of action of SAHA in breast cancer cells remains unclear. In this study, we found that SAHA is equally effective in targeting cells of different breast cancer subtypes and tamoxifen sensitivity. Importantly, we found that down-regulation of survivin plays an important role in SAHA-induced autophagy and cell viability reduction in human breast cancer cells. SAHA decreased survivin and XIAP gene transcription, induced survivin protein acetylation and early nuclear translocation in MCF7 and MDA-MB-231 breast cancer cells. It also reduced survivin and XIAP protein stability in part through modulating the expression and activation of the 26S proteasome and heat-shock protein 90. Interestingly, targeting HDAC3 and HDAC6, but not other HDAC isoforms, by siRNA/pharmacological inhibitors mimicked the effects of SAHA in modulating the acetylation, expression, and nuclear translocation of survivin and induced autophagy in MCF7 and MDA-MB-231 cancer cells. Targeting HDAC3 also mimicked the effect of SAHA in up-regulating the expression and activity of proteasome, which might lead to the reduced protein stability of survivin in breast cancer cells. In conclusion, this study provides new insights into SAHA's molecular mechanism of actions in breast cancer cells. Our findings emphasize the complexity of the regulatory roles in different HDAC isoforms and potentially assist in predicting the mechanism of novel HDAC inhibitors in targeted or combinational therapies in the future.

KW - Breast cancer

KW - HDAC

KW - SAHA

KW - Survivin

KW - XIAP

UR - http://www.scopus.com/inward/record.url?scp=84973163868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973163868&partnerID=8YFLogxK

U2 - 10.3389/fphar.2016.00081

DO - 10.3389/fphar.2016.00081

M3 - Article

VL - 7

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

IS - MAR

M1 - 81

ER -